Stryker Completes Acquisition of Amplitude Vascular Systems: Next-Gen IVL Technology and the Battle for Peripheral Vascular

The Deal at a Glance

On May 7, 2026, Stryker (NYSE: SYK) completed its acquisition of Amplitude Vascular Systems (AVS), a privately held medical device company based in Boston, Massachusetts. The deal, first announced on April 13, 2026, brings next-generation intravascular lithotripsy (IVL) technology into Stryker's peripheral vascular portfolio — and signals the company's intent to become a platform leader in treating calcified peripheral arterial disease (PAD).

Financial terms were not disclosed. The transaction was subject to customary closing conditions and closed less than a month after announcement, reflecting the relatively modest deal size and the strategic clarity of the asset.

What Amplitude Vascular Systems Brings: The IVL Technology

At the core of this acquisition is AVS's intravascular lithotripsy platform, which uses pulsed CO2-generated pressure waves uniformly delivered through an IVL balloon catheter. The mechanism fractures calcium deposits in arterial walls and optimizes luminal gain — the widening of the artery to restore blood flow.

The technology is designed around three key differentiators:

1. Enhanced catheter deliverability — The system is engineered to navigate complex vascular anatomies more effectively than earlier-generation IVL devices.
2. Faster treatment speed — CO2-generated pressure waves can be delivered rapidly, reducing procedure time.
3. Improved therapy efficiency — Uniform pressure wave distribution aims for consistent calcium fracture across the treatment zone.

AVS has made meaningful regulatory progress. The company received an Investigational Device Exemption (IDE) from the FDA for its US pivotal trial and enrolled the first patient in that study for its Pulsatile Intravascular Lithotripsy (PIVL) device. AVS also completed a $36 million Series B funding round to support peripheral commercial launch as well as coronary and carotid IDE trials. The product has not yet received FDA clearance or CE marking, meaning Stryker is acquiring a technology platform with established clinical momentum rather than a commercial revenue stream. This positions the deal as a classic capability-building acquisition — buying innovation with clinical validation and leveraging Stryker's regulatory infrastructure and commercial scale to bring it to market.

Why IVL Matters: The Calcified PAD Problem

Peripheral arterial disease affects an estimated 200+ million people worldwide, with prevalence increasing sharply in populations over 60. Among patients with symptomatic PAD, a significant proportion present with severely calcified lesions — hardened calcium deposits in the arterial walls that make endovascular treatment extremely challenging.

Traditional balloon angioplasty often fails to adequately treat calcified lesions because the calcium resists expansion. Stents may not deploy properly or may fracture. Atherectomy devices (which physically remove plaque) add complexity, cost, and complication risk. IVL addresses this gap by using acoustic pressure waves to fracture calcium from within, creating micro-fractures that allow the artery to expand without the trauma of high-pressure balloon inflation.

The IVL market has been validated by Shockwave Medical, which pioneered IVL for coronary and peripheral applications before being acquired by Johnson & Johnson in 2024 for approximately $13.1 billion (including the acquisition by J&J's MedTech division). Boston Scientific also entered the IVL space by acquiring Bolt, the developer of the Bolt IVL system. FastWave Medical, developing a laser IVL technology, has also gained traction with multiple patents. Shockwave's success demonstrated both the clinical value and commercial potential of IVL technology, creating a new category within interventional cardiology and vascular medicine.

Competitive Landscape: Stryker vs. J&J in IVL

The Stryker-AVS deal cannot be understood without recognizing the competitive context. J&J's acquisition of Shockwave Medical in 2024 gave it a dominant position in the IVL space. Stryker's move is a direct response — a bid to ensure it is not locked out of one of the fastest-growing segments in cardiovascular intervention.

The Broader Cardiovascular Device Consolidation

The cardiovascular device sector has seen intense M&A activity in 2025–2026, driven by the convergence of several trends:

• Aging populations driving higher incidence of calcified vascular disease
• Technological maturation of IVL, drug-coated balloons, and atherectomy
• Scale advantages in sales and distribution for capital-intensive interventional products
• Platform-building strategies by large-cap medtech companies

As one industry commentator noted on LinkedIn: "Stryker's acquisition of Amplitude is a clear shot across the bow in the IVL space. With Shockwave now under J&J, seeing Stryker move into the calcified lesion market is going to make 2026 a very interesting year for peripheral vascular reps."

Stryker's Peripheral Vascular Strategy

Stryker's move into IVL is not an isolated transaction. It is part of a deliberate strategy to build a comprehensive peripheral vascular platform. Kevin Lobo, Stryker's Chair and CEO, stated that the acquisition "represents an important step in advancing our vision to build a comprehensive peripheral vascular platform and address significant unmet clinical needs."

Stryker's existing peripheral vascular portfolio includes thrombectomy devices, embolic protection, and various catheter-based technologies. Adding IVL fills a critical gap — the ability to treat heavily calcified lesions — which is increasingly necessary as the PAD patient population ages and disease complexity increases.

The "all-in-one bag for vascular" concept, referenced by industry observers, reflects the trend toward comprehensive procedure trays that give interventionalists everything they need in a single package. By adding IVL to its portfolio, Stryker moves closer to offering a full procedural solution for peripheral arterial intervention.

Regulatory Pathway Forward

Since the AVS IVL platform has not yet received regulatory clearance, Stryker will need to navigate:

1. FDA 510(k) or De Novo pathway — Depending on whether FDA views the CO2-generated pressure wave technology as substantially equivalent to existing IVL devices (like Shockwave's) or as a novel technology requiring a new classification.
2. CE marking under EU MDR — The EU Medical Device Regulation will require conformity assessment by a notified body, with clinical evidence supporting safety and performance.
3. Clinical data requirements — Stryker may need to generate clinical data to support regulatory submissions, particularly if the CO2-based mechanism differs significantly from existing IVL systems.

The regulatory timeline will be a key factor in determining when Stryker can begin generating revenue from this acquisition. Given the existing IVL predicate devices on the market, a 510(k) pathway may be feasible, potentially enabling FDA clearance within 12–18 months.

Market Opportunity and Financial Context

The Peripheral Vascular Device Market

The global peripheral vascular devices market is estimated at approximately $4–5 billion and growing, driven by:

• Rising prevalence of PAD, particularly in aging and diabetic populations
• Increasing adoption of minimally invasive endovascular techniques over open surgery
• Technology innovation in drug-coated balloons, stents, and atherectomy devices
• Expansion of IVL as a new category addressing previously untreatable calcified lesions

Stryker's Financial Position

Stryker reported revenue of approximately $25.1 billion in 2025 (up 11.2% year over year), with its MedSurg and Neurotechnology and Orthopaedics segments being the primary revenue drivers. The company has historically been disciplined in its acquisition strategy, pursuing tuck-in deals that add capabilities rather than transformational megadeals. The AVS acquisition fits this pattern — it adds a specific technological capability (IVL) to an existing business unit (peripheral vascular) without requiring a large capital outlay or complex integration.

Implications for the MedTech Industry

What This Means for Device Manufacturers

1. IVL is becoming a competitive battleground. With both J&J (Shockwave) and Stryker (AVS) now in the space, and potentially other entrants, IVL technology will evolve rapidly. Companies developing complementary technologies (drug-coated balloons, atherectomy, imaging) should consider how IVL integration affects their value proposition.

2. Platform strategies dominate. The era of single-product medtech companies is fading in cardiovascular intervention. Acquirers want comprehensive portfolios that address the full procedural workflow. For startups, this means building technology that plugs into a larger platform, not just a standalone product.

3. Regulatory precedent helps followers. Shockwave's FDA clearance established the IVL regulatory pathway. Subsequent IVL devices may benefit from this precedent, potentially reducing regulatory timelines and clinical evidence requirements.

What This Means for Hospitals and Physicians

1. More IVL options coming. Competition between J&J/Shockwave and Stryker/AVS will drive innovation and potentially improve pricing dynamics for hospitals.

2. Calcified PAD treatment is evolving. The availability of next-generation IVL platforms will expand the treatable patient population, potentially reducing the need for surgical bypass in heavily calcified disease.

3. Procedure workflow implications. As IVL becomes integrated into broader procedural platforms (like Stryker's "all-in-one" approach), physicians may benefit from streamlined workflows and reduced procedure time.

Key Takeaways

• Stryker completed its acquisition of AVS on May 7, 2026, adding CO2-generated IVL technology to its peripheral vascular portfolio
• The deal is a direct competitive response to J&J's 2024 acquisition of Shockwave Medical, the IVL market leader
• AVS's IVL platform has not yet received regulatory clearance; Stryker will need to navigate FDA and EU MDR pathways
• The acquisition reflects the broader trend of cardiovascular device consolidation and platform-building strategies
• The peripheral vascular device market (~$4–5B) is a high-growth segment driven by aging populations and increasing disease complexity
• For device manufacturers, the deal underscores the importance of IVL as a new therapeutic category and the value of platform-compatible technology